Monday, August 18, 2025
StockstToday.com Logo
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Keybanc Analyst Reiterates Bullish Stance on Schrodinger with Revised Price Target

Elaine Mendonca by Elaine Mendonca
February 29, 2024
in Breaking News
0
Technology Blockchain Markets and money
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Keybanc analyst Scott Schoenhaus has reiterated his bullish stance on Schrodinger (NASDAQ: SDGR), maintaining an Overweight rating on the stock. However, he has revised his price target down from $38 to $33. This adjustment follows his initial target of $38 and indicates a shift in his perspective on the company’s value and future prospects.

SDGR Stock Price Plummets by 18.84% on February 29, 2024: Is a Turnaround on the Horizon?

On February 29, 2024, SDGR stock experienced a significant drop in its price, closing at $25.46, which was a decrease of $5.91 or 18.84% from the previous market close. This drop in price is quite substantial and may have been concerning for investors holding SDGR shares.

However, there was a slight uptick in the stock price during after-hours trading, with SDGR rising $0.14. While this increase is modest, it may provide some hope for investors looking for a potential turnaround in the stock’s performance.

Investors should exercise caution and conduct thorough research before making any investment decisions related to SDGR.

SDGR Stock Analysis: Revenue Growth Amidst Rising Losses and Declining EPS

On February 29, 2024, SDGR stock experienced mixed performances based on the financial data provided by CNN Money. The company’s total revenue for the past year was $180.96 million, which marked a 31.19% increase compared to the previous year. In the third quarter, total revenue was reported at $42.57 million, showing a 20.97% increase from the previous quarter.

However, the company’s net income paints a different picture. SDGR reported a net loss of $149.19 million for the past year, reflecting a 48.6% decrease compared to the previous year. In the third quarter, the net loss was even higher at $62.02 million, representing a significant 1549.84% decrease from the previous quarter.

Earnings per share (EPS) also took a hit for SDGR. The company reported an EPS of -$2.10 for the past year, which was a 47.39% decrease compared to the previous year. In the third quarter, the EPS was even lower at -$0.86, marking a substantial 1612.98% decrease from the previous quarter.

Overall, the financial data shows that SDGR has experienced growth in total revenue but has struggled with increasing losses and declining EPS. Investors may be concerned about the company’s ability to turn its revenue growth into profitability. It will be important for SDGR to address its financial challenges and demonstrate a path towards sustainable growth in order to regain investor confidence and drive stock performance in the future.

Tags: SDGR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Food Producers Stock Bull Market

The Rewarding Investment of McDonalds Stock A 20Year Success Story

Xenon Pharmaceuticals Reports Strong Financial Position and Promising Pipeline for Neurological Disorders

Aerospace and Defense Stock Market Today (1)

Sidus Space Announces Public Offering of Class A Common Stock

Recommended

Insider Activity at Minerals Technologies Raises Questions about Stock Options

2 years ago
Pharmaceutical Markets and money

Gilead Sciences Inc Completes Waiting Period for Tender Offer for CymaBay Therapeutics Inc

1 year ago
Technology Blockchain Markets and money

Analyst Ratings and Price Targets for KLA NASDAQ KLAC

2 years ago
Finance_Credit

Trustco Bank Declares Quarterly Dividend of 36 Cents per Share

1 year ago

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • ETF
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

Topics

AAL AAPL ABNB ADBE ADSK ALB AMD AMZN AVGO BA C CCL CELH COIN COST CRWD CTVA DELL DFS DIS DLR DLTR DWAC GM GRFS IBM INTC JPM KSS LLY META MSFT NFLX NVDA NVO ORCL PARA PLTR PLUG QCOM SMCI TGT TSLA UNH VZ
No Result
View All Result

Highlights

Danaher Stock: Market Experts Divided Amid Earnings Volatility

Institutional Investors Double Down on Ares Capital Despite Earnings Shortfall

Synopsys Stock: Diverging Signals Between Executives and Analysts

Biotech Stock Assembly Biosciences Gains Analyst Backing with $50 Price Target

Could Siemens Healthineers Emerge as the Dark Horse of Medical AI Innovation?

Geely Emerges as China’s Silent Contender in the EV Race

Trending

Axsome Stock
Stocks

Axsome Therapeutics Emerges as a High-Growth Contender in Neurological Drug Development

by Robert Sasse
August 18, 2025
0

Axsome Therapeutics is making waves in the biopharmaceutical sector with its groundbreaking treatments for some of neurology's...

Norfolk Southern Stock

Norfolk Southern Stock Gains Analyst Confidence Amid Operational Challenges

August 18, 2025
Newmont Mining Stock

Institutional Investors Divided on Newmont Mining as Gold Demand Surges

August 18, 2025
Danaher Stock

Danaher Stock: Market Experts Divided Amid Earnings Volatility

August 18, 2025
Ares Capital Stock

Institutional Investors Double Down on Ares Capital Despite Earnings Shortfall

August 18, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • Axsome Therapeutics Emerges as a High-Growth Contender in Neurological Drug Development August 18, 2025
  • Norfolk Southern Stock Gains Analyst Confidence Amid Operational Challenges August 18, 2025
  • Institutional Investors Divided on Newmont Mining as Gold Demand Surges August 18, 2025

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • ETF
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings

© 2023 StocksToday.com